Silverarc Capital Management’s Trevi Therapeutics TRVI Stock Holding History
Bought
Maintained
Sold
Other funds holding TRVI
Silverarc Capital Management's TRVI Position: Q3 2026 in Review
Silverarc Capital Management sold out of Trevi Therapeutics (TRVI) in Q3 2026, closing a stake of 678,095 shares — an estimated $12.6M sold.
Silverarc Capital Management first reported a position in TRVI in Q3 2022 and held it in 16 quarters. The position peaked at $12.6M in Q2 2026. 222 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.
- Silverarc Capital Management reported no remaining Trevi Therapeutics position as of Q3 2026 after selling out during the quarter.
- Silverarc Capital Management sold 678,095 Trevi Therapeutics shares in Q3 2026, an estimated $12.6M.
- Silverarc Capital Management first reported a position in Trevi Therapeutics in Q3 2022 and held it in 16 quarters.
- Silverarc Capital Management's Trevi Therapeutics position peaked at $12.6M in Q2 2026.
- 222 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.
Based on Silverarc Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.